Ardea Biosciences, Inc.
4939 Directors Place
San Diego
California
92121
United States
Tel: 858-652-6500
Fax: 858-652-0760
Website: http://www.ardeabio.com/
Email: info@ardeabio.com
146 articles about Ardea Biosciences, Inc.
-
The San Diego-based immunology company is locating and developing molecules where the mechanism of action has either been proven or makes sense.
-
Brii Biosciences Launches with $260 Million, a Partnership with Vir Biotech, and Other Relationsh...
5/24/2018
Brii Biosciences is launching to accelerate the development and delivery of breakthrough drugs in China with $260 million in financial backing. -
Ardea Biosciences, Inc. HR VP Shares A Fool-Proof Guide To Joining A Startup
11/20/2014
-
AstraZeneca PLC and Ardea Biosciences, Inc. Release: A Large, Observational Study of Common Gout Treatment Allopurinol Shows Less Than Half of Patients Reach Recommended Treatment Goal
10/28/2013
-
AstraZeneca PLC Completes Acquisition of Ardea Biosciences, Inc.
6/20/2012
-
Ardea Biosciences, Inc. Announces Expiration of HSR Waiting Period in Connection With Proposed Merger
6/5/2012
-
Ardea Biosciences, Inc. Earns $7.5 Million Milestone From Bayer HealthCare
5/30/2012
-
Ardea Biosciences, Inc. Announces First Quarter 2012 Financial Results
5/7/2012
-
Law Office of Brodsky & Smith, LLC Announces Investigation of Ardea Biosciences, Inc.
4/25/2012
-
AstraZeneca PLC to Acquire Ardea Biosciences, Inc. for $1.26 Billion Including Lead Product Lesinurad in Phase III Development for Gout
4/23/2012
-
Ardea Biosciences, Inc. Reports Recent Accomplishments and Announces Fourth Quarter and Full-Year 2011 Financial Results
3/9/2012
-
Ardea Biosciences, Inc. to Present at Upcoming Investor Conferences
2/29/2012
-
Ardea Biosciences, Inc. to Present at Upcoming Investor Conferences
2/9/2012
-
Ardea Biosciences, Inc. Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
2/7/2012
-
Ardea Biosciences, Inc. Prices Public Offering of Common Stock
2/1/2012
-
Ardea Biosciences, Inc. Announces Proposed Public Offering of Common Stock
2/1/2012
-
Ardea Biosciences, Inc. Initiates Phase 3 Clinical Development Program for Lesinurad
12/19/2011
-
Ardea Biosciences, Inc. to Present at Upcoming Investor Conferences
11/15/2011
-
Ardea Biosciences, Inc. Provides Additional Positive Clinical Results for Lesinurad and Initial Clinical Results for RDEA3170 at the 2011 ACR/ARHP Annual Scientific Meeting
11/7/2011
-
Ardea Biosciences, Inc. Reports Recent Accomplishments, Important Upcoming Events and Third Quarter 2011 Financial Results
11/4/2011